SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00092391

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Study of M-M-R(TM) II at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age

The purpose of this study is to determine the mumps virus strength at the end of shelf-life (expiration date) of an approved vaccine.

NCT00092391 Measles Mumps Rubella Varicella
MeSH:Rubella Mumps

2 Interventions

Name: Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live

Description: 0.5 mL subcutaneous injection of one of three sub-lots on Day 0
Type: Biological
Group Labels: 3

Control Group Mumps Expiry Group 1 Mumps Expiry Group 2

Name: Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)

Description: 0.5 mL subcutaneous injection on Day 0
Type: Biological
Group Labels: 3

Control Group Mumps Expiry Group 1 Mumps Expiry Group 2


Primary Outcomes

Measure: Neutralizing antibodies to mumps at 6 weeks postvaccination

Time: 6 weeks postvaccination

Secondary Outcomes

Measure: Geometric mean titers to mumps by ELISA at 6 weeks and at 1 year postvaccination

Time: 6 weeks and 1 year postvaccination

Purpose: Prevention

Allocation: Randomized

Single Group Assignment


There is one SNP

SNPs


1 V205C

A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) The purpose of this study is to determine the mumps virus strength at the end of shelf-life (expiration date) of an approved vaccine. --- V205C ---



HPO Nodes